- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06892691
Pleuroscopia Primero versus toracentesis primero en pacientes con sospechosas de efusiones pleurales malignas (PERFECT-MPE)
This is a randomized control trial of patients with suspected malignant pleural effusions to compare whether patients who have a thoracentesis or pleuroscopy (pleural biopsy) obtain an adequate biopsy, achieve a diagnosis, and begin cancer-directed therapy faster.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a randomized control trial of patients with suspected malignant pleural effusions comparing patients who undergo either pleuroscopy or thoracentesis as the first diagnostic test. Both procedures are considered standard of care for this diagnosis but it is unknown which one provides more adequate biopsy samples and achieves faster diagnosis and shorter time to oncologic treatment. Currently, most patients undergo thoracentesis first and, if this is inadequate for diagnosis, they then undergo pleuroscopy for further biopsy samples. This study seeks to assess whether patients who undergo pleuroscopy as the first test obtain adequate biopsy samples and a faster path to further oncologic care compared to patients who undergo thoracentesis first. Patients will be recruited and randomized in a 1:1 manner.
Ultrasound is routinely used prior to the procedure and a chest x-ray is done after the procedure. Any other imaging will be determined by clinic need only. No imaging will be done for research purposes. No additional samples will be collected other than what is necessary for diagnostic purposes. In patients who have a non-diagnostic thoracentesis, the participants will be referred for pleuroscopy as the next diagnostic step. In the rare case that pleuroscopy does not achieve adequate diagnosis, the next step would be a liquid biopsy (non-invasive serologic testing for oncologic markers.) The need for liquid biopsy in participants in this study will be determined on a case-by-case basis depending on the clinical concern for malignancy.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10019
- Mount Sinai West
-
New York, New York, Estados Unidos, 10029
- Mount Sinai Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Referral for diagnostic pleural procedure.
- Age ≥ 18 years.
- Suspected malignant pleural effusion (Suggestive radiologic appearance (based on computed tomography or positron emission tomography) OR suspected cancer with associated effusion.)
Exclusion Criteria:
- Inability to provide informed consent.
- Needs emergent drainage.
- Pleural effusion is known to be malignant.
- Suspected transudative, infectious or inflammatory effusion etiology.
- Having prior inconclusive/non-diagnostic thoracentesis or pleuroscopy.
- Patient is deemed by the clinical team to be more appropriate for VATS biopsy.
- Terminally ill patients in whom a diagnosis will not change management, or who is unlikely to be a candidate for oncological treatment due to significant comorbidities.
- Pregnancy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Pleuroscopy first
Participants will undergo pleuroscopy first |
Pleuroscopies are performed under moderate sedation with local anesthesia. Through a 1-cm incision a camera is introduced into the pleural space and the space is inspected after draining all fluid. Targeted biopsies under direct visualization are obtained using forceps. The aspirated fluid and biopsies obtained are sent to the cytology and pathology laboratories for analysis. |
|
Comparador activo: Thoracentesis first
Participants will undergo thoracentesis first |
Thoracenteses are performed under local anesthesia with the insertion of a 5-8Fr catheter into the pleural space. The aspirated fluid obtained is sent to the cytology laboratory for analysis. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proportion of biopsies adequate for definitive diagnosis
Periodo de tiempo: 6 months
|
Proportion of biopsies adequate for definitive diagnosis |
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time from initial visit with pulmonologist to procedure
Periodo de tiempo: 6 months
|
Time from initial visit with pulmonologist to procedure |
6 months
|
|
Time from initial procedure to diagnosis
Periodo de tiempo: 6 months
|
Time from initial procedure to diagnosis |
6 months
|
|
Time from initial visit with pulmonologist to diagnosis
Periodo de tiempo: 6 months
|
Time from initial visit with pulmonologist to diagnosis |
6 months
|
|
Time from initial visit with pulmonologist to seeing oncologist
Periodo de tiempo: 6 months
|
Time from initial visit with pulmonologist to seeing oncologist |
6 months
|
|
Time from initial visit with pulmonologist to starting treatment
Periodo de tiempo: 6 months
|
Time from initial visit with pulmonologist to starting treatment |
6 months
|
|
Time from seeing oncologist to starting treatment
Periodo de tiempo: 6 months
|
Time from seeing oncologist to starting treatment |
6 months
|
|
Frequency of procedure-related complications
Periodo de tiempo: 6 months
|
Frequency of procedure-related complications |
6 months
|
|
Frequency of additional diagnostic testing
Periodo de tiempo: 6 months
|
Frequency of additional diagnostic testing |
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Udit Chaddha, MBBS, MOUNT SINAI HOSPITAL
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STUDY-24-00999
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All of the individual participant data collected during the trial, after deidentification.
Marco de tiempo para compartir IPD
Immediately following publication. No end date.
Criterios de acceso compartido de IPD
Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose.
Any purpose. Proposals should be directed to udit.chaddha@mssm.edu. To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link tbd).
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .